[青光眼视网膜神经保护药物的研究进展]。

X Y Liu, X H Sun
{"title":"[青光眼视网膜神经保护药物的研究进展]。","authors":"X Y Liu, X H Sun","doi":"10.3760/cma.j.cn112142-20240502-00203","DOIUrl":null,"url":null,"abstract":"<p><p>Glaucoma is a neural degenerative disease characterized by progressive loss of retinal ganglion cells, resulting in irreversible visual field loss, low vision, and total blindness. Despite the fact that the pathological elevation of intraocular pressure is a major risk factor for glaucoma, it is imperative to develop therapies that can prevent and block retinal ganglion cell injury and apoptosis in addition to reducing intraocular pressure. Drug therapy is the primary treatment for glaucoma in most clinical cases. This article provides reference information for the clinical treatment of glaucoma by summarizing and analyzing the medications that have direct optic nerve protection in clinical or preclinical trials, based on the most recent research results from both domestic and international studies.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"60 10","pages":"860-869"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Research progress of retinal neuroprotective drugs for glaucoma].\",\"authors\":\"X Y Liu, X H Sun\",\"doi\":\"10.3760/cma.j.cn112142-20240502-00203\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Glaucoma is a neural degenerative disease characterized by progressive loss of retinal ganglion cells, resulting in irreversible visual field loss, low vision, and total blindness. Despite the fact that the pathological elevation of intraocular pressure is a major risk factor for glaucoma, it is imperative to develop therapies that can prevent and block retinal ganglion cell injury and apoptosis in addition to reducing intraocular pressure. Drug therapy is the primary treatment for glaucoma in most clinical cases. This article provides reference information for the clinical treatment of glaucoma by summarizing and analyzing the medications that have direct optic nerve protection in clinical or preclinical trials, based on the most recent research results from both domestic and international studies.</p>\",\"PeriodicalId\":39688,\"journal\":{\"name\":\"中华眼科杂志\",\"volume\":\"60 10\",\"pages\":\"860-869\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华眼科杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112142-20240502-00203\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华眼科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112142-20240502-00203","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

青光眼是一种神经退行性疾病,其特点是视网膜神经节细胞逐渐丧失,导致不可逆转的视野缺损、低视力和完全失明。尽管病理性眼压升高是青光眼的主要风险因素,但当务之急是开发出除降低眼压外,还能预防和阻止视网膜神经节细胞损伤和凋亡的疗法。在大多数临床病例中,药物治疗是青光眼的主要治疗方法。本文根据国内外最新研究成果,总结分析了在临床或临床前试验中对视神经有直接保护作用的药物,为青光眼的临床治疗提供参考信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Research progress of retinal neuroprotective drugs for glaucoma].

Glaucoma is a neural degenerative disease characterized by progressive loss of retinal ganglion cells, resulting in irreversible visual field loss, low vision, and total blindness. Despite the fact that the pathological elevation of intraocular pressure is a major risk factor for glaucoma, it is imperative to develop therapies that can prevent and block retinal ganglion cell injury and apoptosis in addition to reducing intraocular pressure. Drug therapy is the primary treatment for glaucoma in most clinical cases. This article provides reference information for the clinical treatment of glaucoma by summarizing and analyzing the medications that have direct optic nerve protection in clinical or preclinical trials, based on the most recent research results from both domestic and international studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
中华眼科杂志
中华眼科杂志 Medicine-Ophthalmology
CiteScore
0.80
自引率
0.00%
发文量
12700
期刊最新文献
[Efficacy of modified nasal transposition of the split lateral rectus muscle for large-angle exotropia from oculomotor nerve palsy]. [Further raising prevention and treatment for amblyopia in China]. [Methotrexate therapy for primary intraocular lymphoma: a case report]. [Paying attention to problems and countermeasures in intermittent exotropia surgery]. [Paying attention to the management of blinding complications caused by early-onset high myopia in children].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1